
Please try another search
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company was founded in 1996 and is based in King Of Prussia, Pennsylvania with an additional office in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Aleks Engel | - | 2023 | Director |
Adam Dilluvio | - | 2023 | Director |
Stacey D. Seltzer | 46 | 2023 | Director |
Dan Wichman | - | 2024 | Director |
Nithya Desikan | 45 | 2023 | Director |
Cyrus David Jilla | 56 | - | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review